Manoj M Pillai, MBBS
Biography
With an interest in blood cells and how they develop, Manoj J. Pillai, MBBS (a medical degree awarded in several countries outside of the U.S.), always knew he would become a hematologist—a physician who treats blood, bone marrow, and lymph system disorders.
Blood production is a complex process that occurs within specific areas of bone marrow. Every day, healthy individuals produce more than a trillion blood cells. In blood disorders, like leukemia, the process of blood cell development is interrupted.
Dr. Pillai began his training at a time when next-generation sequencing, which allows researchers to quickly determine genetic ordering and structure, was at its start. Since then, Dr. Pillai and his team have integrated these fine-tuned approaches in their work, exploring what leads to oncogenesis—the mutation of regular blood cells.
This information leads to “precision genetic therapies,” which allow doctors to target specific approaches to a patient’s cancer based on their genetic make-up.
Cancer is not a single disease and so each type of cancer will respond differently, but the goal, ultimately is to develop targeted therapies that make toxic treatments such as chemotherapy a thing of the past, Dr. Pillai says.
Dr. Pillai’s research explores different ways blood cells develop abnormally and also specific mutations that can lead to cancers.
Titles
- Associate Professor of Medicine (Hematology)
Education & Training
- Instructor and Research AssociateFred Hutchinson Cancer Research Center (2008)
- FellowFred Hutchinson Cancer Research Center/ University of Washington (2005)
- ResidentBaylor College of Medicine (2002)
- MBBSAll India Institute of Medical Sciences (1998)
Additional Information
- Cancer Research Fellow of the Ladies Auxiliary to the Veterans of Foreign Wars of the United States: (2005)
- Travel Grant, American Society of Hematology: (2004)
- NIH/NCI Training Grant, Fred Hutchinson Cancer Research Center, University of Washington: (2003)
- Sir Dorabji Tata Prize for Best Undergraduate in Biochemistry: (1994)
- 8th position nationwide in All India Central Board of Secondary Education’s Pre-Medical Examination: (1992)
- National Talent Search Exam (NTSE) Scholar, National Council for Education Research and Training (NCERT), India: (1990)
- Olazabal-Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Teng Y, Lan L, Chen X, Pei H, Pillai M, Sung P, Kupfer G. Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA export Cancer Research 2023, 83: 6100-6100. DOI: 10.1158/1538-7445.am2023-6100.
- Olazabal Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Lan L, Pillai M, Sung P, Kupfer G. Complex Formation between FANCD2 and the Splicing Factor SRSF1 Helps Prevent R-Loop Accumulation through mRNA Export Regulation Blood 2022, 140: 5828-5829. DOI: 10.1182/blood-2022-166798.
- Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT, Verma A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations ELife 2022, 11: e78136. PMID: 36040792, PMCID: PMC9427103, DOI: 10.7554/elife.78136.
- Karmakar S, Ramirez O, Paul KV, Gupta AK, Kumari V, Botti V, de los Mozos IR, Neuenkirchen N, Ross RJ, Karanicolas J, Neugebauer KM, Pillai MM. Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2) NAR Cancer 2022, 4: zcac015. PMID: 35528200, PMCID: PMC9070473, DOI: 10.1093/narcan/zcac015.
- Liang F, Nagarajan A, Pillai M, Sung P, Kupfer G. Fanci-FANCD2 Promotes Genome Stability and DNA Repair By Down-Regulating BLM Helicase Activity Blood 2021, 138: 1113-1113. DOI: 10.1182/blood-2021-152218.
- Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase Communications Biology 2021, 4: 1184. PMID: 34645977, PMCID: PMC8514589, DOI: 10.1038/s42003-021-02690-1.
- Boddu P, Gupta A, Waldman T, Pillai M. 40008 COMBINED CRISPR/CAS9 AND AAV FOR THE GENERATION OF CONDITIONAL ISOGENIC GENE KNOCK-INS Journal Of Clinical And Translational Science 2021, 5: 22-22. PMCID: PMC8827824, DOI: 10.1017/cts.2021.460.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Olazabal-Herrero A, Green A, Chen X, Sung P, Pillai M, Kupfer G. Binding of FANCD2 to SRSF1 Splicing Factor Prevents Genomic Instability through R Loop Regulation Blood 2020, 136: 19-19. DOI: 10.1182/blood-2020-141369.
- Marczyk M, Patwardhan GA, Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells Cancers 2020, 12: 2551. PMID: 32911681, PMCID: PMC7563413, DOI: 10.3390/cancers12092551.
- Marczyk M, Gunasekharan V, Zhao J, Qu R, Li X, Patwardhan G, Wali V, Gupta A, Pillai M, Kluger Y, Hatzis C, Pusztai L. Abstract 6333: Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment Cancer Research 2020, 80: 6333-6333. DOI: 10.1158/1538-7445.am2020-6333.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience* Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Bewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Shallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- Biancon G, Joshi P, Hunck T, Gao Y, Botti V, Qin A, Sadykov M, Wang X, Viero G, Neuenkirchen N, Taylor A, Huang J, Ardasheva A, Fu X, Lin H, Pillai M, Kielkopf C, Neugebauer K, Tebaldi T, Halene S. U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex Blood 2019, 134: 1230-1230. DOI: 10.1182/blood-2019-130759.
- Choudhary G, Smith M, Pellagatti A, Bhagat T, Gordon S, Pandey S, Shah N, Aluri S, Booher R, Ramachandra M, Samson M, Pradhan K, Bowman T, Pillai M, Guha C, Wickrema A, Will B, Shastri A, Steidl U, Boultwood J, Starczynowski D, Verma A. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML Blood 2019, 134: 4224-4224. DOI: 10.1182/blood-2019-124458.
- Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
- Shallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
- Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen Clinical Cancer Research 2017, 23: 1710-1721. PMID: 27702820, PMCID: PMC5378660, DOI: 10.1158/1078-0432.ccr-15-2851.
- Ramirez O, Kesarwani A, Abhishek G, Minella A, Pillai M. Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia Blood 2016, 128: 1881-1881. DOI: 10.1182/blood.v128.22.1881.1881.
- Murthy T, Bluemn T, Pillai M, Minella A. SF3B1 Interactions with Chromatin Are Dynamic and Regulated in a Cell Cycle-Dependent Manner Blood 2016, 128: 1480-1480. DOI: 10.1182/blood.v128.22.1480.1480.
- Rejeski K, Liang Y, Tebaldi T, Stefani G, Taylor A, Maziarz J, Song Y, Balasubramanian K, Vasic R, Kapetanovic E, Abdel-Wahab O, Pillai M, Halene S. Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia Blood 2015, 126: 141-141. DOI: 10.1182/blood.v126.23.141.141.
- Minella A, Ramirez O, Xu Y, Murthy T, Yang X, Pillai M. Expression Of Mutant Spliceosomal Protein SF3B1 Results In Dysregulated Hematopoietic Maturation Blood 2013, 122: 2773-2773. DOI: 10.1182/blood.v122.21.2773.2773.
- Ramakrishnan A, Torok-Storb B, Pillai M. Primary Marrow-Derived Stromal Cells: Isolation and Manipulation 2013, 1035: 75-101. PMID: 23959984, PMCID: PMC3748384, DOI: 10.1007/978-1-62703-508-8_8.
- Ramakrishnan A, Pillai M, Torok-Storb B. The Adult Stem Cell Niche 2013, 15-30. DOI: 10.1007/978-1-4614-9569-7_2.
- Kabos P, Kline E, Brown J, Flory K, Sartorius C, Hesselberth J, Pillai M. Abstract PD01-07: High throughput sequencing following cross-linked immune-precipitation (HITS-CLIP) of Argonaute protein reveals novel miRNA regulatory pathways of Estrogen Receptor in breast cancer. Cancer Research 2012, 72: pd01-07-pd01-07. DOI: 10.1158/0008-5472.sabcs12-pd01-07.
- Yang X, Balakrishnan I, Torok-Storb B, Pillai M. Marrow Stromal Cell Infusion Rescues Hematopoiesis in Lethally Irradiated Mice despite Rapid Clearance after Infusion Advances In Hematology 2012, 2012: 142530. PMID: 22400029, PMCID: PMC3287024, DOI: 10.1155/2012/142530.
- Yang X, Balakrishnan I, Torok-Storb B, Pillai M. Marrow Stromal Cells (MSC) Rescue Hematopoiesis in Lethally Irradiated Mice Despite Rapid Clearance After Infusion, Blood 2011, 118: 3406-3406. DOI: 10.1182/blood.v118.21.3406.3406.
- Balakrishnan I, Yang X, Torok-Storb B, Hesselberth J, Pillai M. High Throughput Sequencing Following Cross-Linked Immune Precipitation (HITS-CLIP) of Argonaute (AGO) Identifies Mir-9 As a Regulator of MMP2 in the Marrow Microenvironment (ME) Blood 2011, 118: 2392-2392. DOI: 10.1182/blood.v118.21.2392.2392.
- Pillai M, Yang X, Balakrishnan I, Bemis L, Torok-Storb B. MiR-886-3p Down Regulates CXCL12 (SDF1) Expression in Human Marrow Stromal Cells PLOS ONE 2010, 5: e14304. PMID: 21179442, PMCID: PMC3001477, DOI: 10.1371/journal.pone.0014304.
- Balakrishnan I, Yang X, Torok-Storb B, Hesselberth J, Pillai M. High Throughput Sequencing Following Cross-Linked Immune Precipitation (HITS-CLIP) of Argonaute (AGO) Identifies Mir-193a as a Regulator of Jagged1 In Marrow Stromal Cells. Blood 2010, 116: 3847-3847. DOI: 10.1182/blood.v116.21.3847.3847.
- Pillai M, Yang X, Iwata M, Bemis L, Torok-Storb B. Mir-886-3p Contributes to the Regulation of the hematopoietic microenvironment by down-Regulating SDF-1α (CXCL12). Blood 2009, 114: 561-561. DOI: 10.1182/blood.v114.22.561.561.
- Iwata M, Pillai M, Ramakrishnan A, Hackman R, Deeg H, Opdenakker G, Torok-Storb B. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity Blood 2006, 109: 85-92. PMID: 16954500, PMCID: PMC1785081, DOI: 10.1182/blood-2006-05-020289.
- Iwata M, Pillai M, Deeg H, Opdenakker G, Torok-Storb B. Inducible Levels of Gelatinase B/Matrix Metalloproteinase-9 Gene Expression in Monocytes Are Associated with Marrow Cellularity in Myelodysplastic Syndrome (MDS). Blood 2005, 106: 1391-1391. DOI: 10.1182/blood.v106.11.1391.1391.
- Pillai M, Iwata M, Dahlen D, Torok-Storb B. Human Marrow Stromal Cells Activate Monocytes to Secrete CXCL7 Peptides, Which Alter the Composition of the Hematopoietic Microenvironment (ME). Blood 2004, 104: 668-668. DOI: 10.1182/blood.v104.11.668.668.
Biography
With an interest in blood cells and how they develop, Manoj J. Pillai, MBBS (a medical degree awarded in several countries outside of the U.S.), always knew he would become a hematologist—a physician who treats blood, bone marrow, and lymph system disorders.
Blood production is a complex process that occurs within specific areas of bone marrow. Every day, healthy individuals produce more than a trillion blood cells. In blood disorders, like leukemia, the process of blood cell development is interrupted.
Dr. Pillai began his training at a time when next-generation sequencing, which allows researchers to quickly determine genetic ordering and structure, was at its start. Since then, Dr. Pillai and his team have integrated these fine-tuned approaches in their work, exploring what leads to oncogenesis—the mutation of regular blood cells.
This information leads to “precision genetic therapies,” which allow doctors to target specific approaches to a patient’s cancer based on their genetic make-up.
Cancer is not a single disease and so each type of cancer will respond differently, but the goal, ultimately is to develop targeted therapies that make toxic treatments such as chemotherapy a thing of the past, Dr. Pillai says.
Dr. Pillai’s research explores different ways blood cells develop abnormally and also specific mutations that can lead to cancers.
Titles
- Associate Professor of Medicine (Hematology)
Education & Training
- Instructor and Research AssociateFred Hutchinson Cancer Research Center (2008)
- FellowFred Hutchinson Cancer Research Center/ University of Washington (2005)
- ResidentBaylor College of Medicine (2002)
- MBBSAll India Institute of Medical Sciences (1998)
Additional Information
- Cancer Research Fellow of the Ladies Auxiliary to the Veterans of Foreign Wars of the United States: (2005)
- Travel Grant, American Society of Hematology: (2004)
- NIH/NCI Training Grant, Fred Hutchinson Cancer Research Center, University of Washington: (2003)
- Sir Dorabji Tata Prize for Best Undergraduate in Biochemistry: (1994)
- 8th position nationwide in All India Central Board of Secondary Education’s Pre-Medical Examination: (1992)
- National Talent Search Exam (NTSE) Scholar, National Council for Education Research and Training (NCERT), India: (1990)
- Olazabal-Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Teng Y, Lan L, Chen X, Pei H, Pillai M, Sung P, Kupfer G. Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA export Cancer Research 2023, 83: 6100-6100. DOI: 10.1158/1538-7445.am2023-6100.
- Olazabal Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Lan L, Pillai M, Sung P, Kupfer G. Complex Formation between FANCD2 and the Splicing Factor SRSF1 Helps Prevent R-Loop Accumulation through mRNA Export Regulation Blood 2022, 140: 5828-5829. DOI: 10.1182/blood-2022-166798.
- Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT, Verma A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations ELife 2022, 11: e78136. PMID: 36040792, PMCID: PMC9427103, DOI: 10.7554/elife.78136.
- Karmakar S, Ramirez O, Paul KV, Gupta AK, Kumari V, Botti V, de los Mozos IR, Neuenkirchen N, Ross RJ, Karanicolas J, Neugebauer KM, Pillai MM. Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2) NAR Cancer 2022, 4: zcac015. PMID: 35528200, PMCID: PMC9070473, DOI: 10.1093/narcan/zcac015.
- Liang F, Nagarajan A, Pillai M, Sung P, Kupfer G. Fanci-FANCD2 Promotes Genome Stability and DNA Repair By Down-Regulating BLM Helicase Activity Blood 2021, 138: 1113-1113. DOI: 10.1182/blood-2021-152218.
- Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase Communications Biology 2021, 4: 1184. PMID: 34645977, PMCID: PMC8514589, DOI: 10.1038/s42003-021-02690-1.
- Boddu P, Gupta A, Waldman T, Pillai M. 40008 COMBINED CRISPR/CAS9 AND AAV FOR THE GENERATION OF CONDITIONAL ISOGENIC GENE KNOCK-INS Journal Of Clinical And Translational Science 2021, 5: 22-22. PMCID: PMC8827824, DOI: 10.1017/cts.2021.460.
- Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Olazabal-Herrero A, Green A, Chen X, Sung P, Pillai M, Kupfer G. Binding of FANCD2 to SRSF1 Splicing Factor Prevents Genomic Instability through R Loop Regulation Blood 2020, 136: 19-19. DOI: 10.1182/blood-2020-141369.
- Marczyk M, Patwardhan GA, Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells Cancers 2020, 12: 2551. PMID: 32911681, PMCID: PMC7563413, DOI: 10.3390/cancers12092551.
- Marczyk M, Gunasekharan V, Zhao J, Qu R, Li X, Patwardhan G, Wali V, Gupta A, Pillai M, Kluger Y, Hatzis C, Pusztai L. Abstract 6333: Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment Cancer Research 2020, 80: 6333-6333. DOI: 10.1158/1538-7445.am2020-6333.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience* Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Bewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Shallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- Biancon G, Joshi P, Hunck T, Gao Y, Botti V, Qin A, Sadykov M, Wang X, Viero G, Neuenkirchen N, Taylor A, Huang J, Ardasheva A, Fu X, Lin H, Pillai M, Kielkopf C, Neugebauer K, Tebaldi T, Halene S. U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex Blood 2019, 134: 1230-1230. DOI: 10.1182/blood-2019-130759.
- Choudhary G, Smith M, Pellagatti A, Bhagat T, Gordon S, Pandey S, Shah N, Aluri S, Booher R, Ramachandra M, Samson M, Pradhan K, Bowman T, Pillai M, Guha C, Wickrema A, Will B, Shastri A, Steidl U, Boultwood J, Starczynowski D, Verma A. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML Blood 2019, 134: 4224-4224. DOI: 10.1182/blood-2019-124458.
- Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
- Shallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
- Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen Clinical Cancer Research 2017, 23: 1710-1721. PMID: 27702820, PMCID: PMC5378660, DOI: 10.1158/1078-0432.ccr-15-2851.
- Ramirez O, Kesarwani A, Abhishek G, Minella A, Pillai M. Integrative Analysis of RNA-Interactome and Translatome Reveal Functional Targets of MSI2 in Myeloid Leukemia Blood 2016, 128: 1881-1881. DOI: 10.1182/blood.v128.22.1881.1881.
- Murthy T, Bluemn T, Pillai M, Minella A. SF3B1 Interactions with Chromatin Are Dynamic and Regulated in a Cell Cycle-Dependent Manner Blood 2016, 128: 1480-1480. DOI: 10.1182/blood.v128.22.1480.1480.
- Rejeski K, Liang Y, Tebaldi T, Stefani G, Taylor A, Maziarz J, Song Y, Balasubramanian K, Vasic R, Kapetanovic E, Abdel-Wahab O, Pillai M, Halene S. Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia Blood 2015, 126: 141-141. DOI: 10.1182/blood.v126.23.141.141.
- Minella A, Ramirez O, Xu Y, Murthy T, Yang X, Pillai M. Expression Of Mutant Spliceosomal Protein SF3B1 Results In Dysregulated Hematopoietic Maturation Blood 2013, 122: 2773-2773. DOI: 10.1182/blood.v122.21.2773.2773.
- Ramakrishnan A, Torok-Storb B, Pillai M. Primary Marrow-Derived Stromal Cells: Isolation and Manipulation 2013, 1035: 75-101. PMID: 23959984, PMCID: PMC3748384, DOI: 10.1007/978-1-62703-508-8_8.
- Ramakrishnan A, Pillai M, Torok-Storb B. The Adult Stem Cell Niche 2013, 15-30. DOI: 10.1007/978-1-4614-9569-7_2.
- Kabos P, Kline E, Brown J, Flory K, Sartorius C, Hesselberth J, Pillai M. Abstract PD01-07: High throughput sequencing following cross-linked immune-precipitation (HITS-CLIP) of Argonaute protein reveals novel miRNA regulatory pathways of Estrogen Receptor in breast cancer. Cancer Research 2012, 72: pd01-07-pd01-07. DOI: 10.1158/0008-5472.sabcs12-pd01-07.
- Yang X, Balakrishnan I, Torok-Storb B, Pillai M. Marrow Stromal Cell Infusion Rescues Hematopoiesis in Lethally Irradiated Mice despite Rapid Clearance after Infusion Advances In Hematology 2012, 2012: 142530. PMID: 22400029, PMCID: PMC3287024, DOI: 10.1155/2012/142530.
- Yang X, Balakrishnan I, Torok-Storb B, Pillai M. Marrow Stromal Cells (MSC) Rescue Hematopoiesis in Lethally Irradiated Mice Despite Rapid Clearance After Infusion, Blood 2011, 118: 3406-3406. DOI: 10.1182/blood.v118.21.3406.3406.
- Balakrishnan I, Yang X, Torok-Storb B, Hesselberth J, Pillai M. High Throughput Sequencing Following Cross-Linked Immune Precipitation (HITS-CLIP) of Argonaute (AGO) Identifies Mir-9 As a Regulator of MMP2 in the Marrow Microenvironment (ME) Blood 2011, 118: 2392-2392. DOI: 10.1182/blood.v118.21.2392.2392.
- Pillai M, Yang X, Balakrishnan I, Bemis L, Torok-Storb B. MiR-886-3p Down Regulates CXCL12 (SDF1) Expression in Human Marrow Stromal Cells PLOS ONE 2010, 5: e14304. PMID: 21179442, PMCID: PMC3001477, DOI: 10.1371/journal.pone.0014304.
- Balakrishnan I, Yang X, Torok-Storb B, Hesselberth J, Pillai M. High Throughput Sequencing Following Cross-Linked Immune Precipitation (HITS-CLIP) of Argonaute (AGO) Identifies Mir-193a as a Regulator of Jagged1 In Marrow Stromal Cells. Blood 2010, 116: 3847-3847. DOI: 10.1182/blood.v116.21.3847.3847.
- Pillai M, Yang X, Iwata M, Bemis L, Torok-Storb B. Mir-886-3p Contributes to the Regulation of the hematopoietic microenvironment by down-Regulating SDF-1α (CXCL12). Blood 2009, 114: 561-561. DOI: 10.1182/blood.v114.22.561.561.
- Iwata M, Pillai M, Ramakrishnan A, Hackman R, Deeg H, Opdenakker G, Torok-Storb B. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity Blood 2006, 109: 85-92. PMID: 16954500, PMCID: PMC1785081, DOI: 10.1182/blood-2006-05-020289.
- Iwata M, Pillai M, Deeg H, Opdenakker G, Torok-Storb B. Inducible Levels of Gelatinase B/Matrix Metalloproteinase-9 Gene Expression in Monocytes Are Associated with Marrow Cellularity in Myelodysplastic Syndrome (MDS). Blood 2005, 106: 1391-1391. DOI: 10.1182/blood.v106.11.1391.1391.
- Pillai M, Iwata M, Dahlen D, Torok-Storb B. Human Marrow Stromal Cells Activate Monocytes to Secrete CXCL7 Peptides, Which Alter the Composition of the Hematopoietic Microenvironment (ME). Blood 2004, 104: 668-668. DOI: 10.1182/blood.v104.11.668.668.